Scott Hubosky, MD
Urology · Philadelphia, PANPI 1669451605
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,165 of the $8,779 with a category attached, or 70.2%. Boston Scientific accounts for 86.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $2,519 and has fallen 91.4% since, to $216 in 2025.
Across 56 payments — averaging $156.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$8K
- C. R. Bard, Inc. & Subsidiaries$465
- Calyxo, Inc.$155
- Myriad Genetic Laboratories, Inc.$137
- Ambu Inc.$119
- Johnson & Johnson$65
- plus $227 from 7 others
Across 1 payment — averaging $352.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$352
What the payments were for
- Consulting fees$6,16570%
- Food & beverage$2,61430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $7,611 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $465 |
| Calyxo, Inc. | 4 | $155 |
| Myriad Genetic Laboratories, Inc. | 3 | $137 |
| Ambu Inc. | 1 | $119 |
| Johnson & Johnson | 3 | $65 |
| Urogen Pharma, Inc. | 2 | $60 |
| Corcept Therapeutics | 2 | $48 |
| Smith+Nephew | 1 | $32 |
| Coloplast | 2 | $30 |
| Telix Pharmaceuticals | 1 | $23 |
| AbbVie | 1 | $19 |
| Photocure Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$4,019
- LithoVue$507
- Prolaris$111
- SpaceOAR VUE System - 10mL$102
How this compares
$8,779 in reported general payments places this provider in the 80th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 350 | $5,881 |
| Potassium Citrate ErPotassium Citrate | 35 | $4,426 |
| Finasteride | 116 | $2,127 |
| Dutasteride | 26 | $729 |
| Penicillin V Potassium | 62 | $522 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 20 | $464 |
| Allopurinol | 16 | $343 |
| Chlorthalidone | 14 | $297 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 35 | $262 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $188 |
| Oxybutynin Chloride | 28 | $163 |
| Cephalexin | 16 | $102 |
| Ciprofloxacin Hcl | 15 | $78 |
Paid to pharmacies, not to this prescriber.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.